Pancreatic Cancer

Onivyde Approved for Pancreatic Cancer (11-3-2015)

The United States Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection) to be used in combination with fluorouracil and leucovorin for patients with advanced pancreatic cancer. The approval is indicated for patients with... Continue Reading

Protein Circulating in Blood Could Be Key to Early Diagnosis of Pancreatic Cancer (08-6-2015)

Research suggests a promising new way to screen for and detect early pancreatic cancer. Certain proteins that circulate in the blood may help identify patients with this disease, for which there’s currently no reliable screening. These findings were... Continue Reading

“Boosted” Radiation Dose May Make Some Pancreatic Cancers Resectable (06-24-2015)

Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more... Continue Reading

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer (11-26-2014)

The U. S. Food and Drug Administration (FDA) has granted MM- 398 plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer, based on data from the phase III NAPOLI-1 study... Continue Reading

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer (10-7-2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer (09-23-2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival (07-10-2014)

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (gemcitabine).... Continue Reading

Aspirin Reduces Risk of Pancreatic Cancer (07-1-2014)

The results of a recent study suggest that regular aspirin use reduces the risk of pancreatic cancer by half.  Clinical studies have also found that regular aspirin use can reduce the risk for colon, esophageal, lung and prostate cancers, as well as... Continue Reading

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy (07-1-2014)

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated patients with metastatic pancreatic cancer... Continue Reading

Ruxolitinib Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation (06-2-2014)

In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that treatment with ruxolitinib plus capecitabine improved overall survival and progression-free survival in metastatic pancreatic cancer... Continue Reading

« Previous PageNext Page »